Literature DB >> 23955320

Neuroprotection in multiple sclerosis: a therapeutic approach.

Amir-Hadi Maghzi1, Alireza Minagar, Emmanuelle Waubant.   

Abstract

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that is pathologically characterized by inflammatory demyelination and neurodegeneration. Axonal damage, along with neuronal loss, occurs from disease onset and may lead to progressive and permanent disability. In contrast with the inflammatory pathways, the molecular mechanisms leading to MS neurodegeneration remain largely elusive. With improved understanding of these mechanisms, new potential therapeutic targets for neuroprotection have emerged. We review the current understanding of neurodegenerative processes at play in MS and discuss potential outcome measures and targets for neuroprotection trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23955320     DOI: 10.1007/s40263-013-0093-7

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  208 in total

1.  Axonal injury in multiple sclerosis.

Authors:  H Lassmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

2.  Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response.

Authors:  M Dalal; S Kim; R R Voskuhl
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

3.  Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques.

Authors:  F Durand-Dubief; B Belaroussi; J P Armspach; M Dufour; S Roggerone; S Vukusic; S Hannoun; D Sappey-Marinier; C Confavreux; F Cotton
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-12       Impact factor: 3.825

4.  Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.

Authors:  Shiv Saidha; Stephanie B Syc; Mary K Durbin; Christopher Eckstein; Jonathan D Oakley; Scott A Meyer; Amy Conger; Teresa C Frohman; Scott Newsome; John N Ratchford; Elliot M Frohman; Peter A Calabresi
Journal:  Mult Scler       Date:  2011-08-24       Impact factor: 6.312

5.  Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis.

Authors:  Orhan Aktas; Timour Prozorovski; Alina Smorodchenko; Nicolai E Savaskan; Roland Lauster; Peter-Michael Kloetzel; Carmen Infante-Duarte; Stefan Brocke; Frauke Zipp
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

6.  Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin.

Authors:  Ajaib Singh Paintlia; Manjeet Kaur Paintlia; Avtar Kaur Singh; Romesh Stanislaus; Anne Genevieve Gilg; Ernest Barbosa; Inderjit Singh
Journal:  J Neurosci Res       Date:  2004-07-01       Impact factor: 4.164

7.  The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study.

Authors:  R K Zabad; L M Metz; T R Todoruk; Y Zhang; J R Mitchell; M Yeung; D G Patry; R B Bell; V W Yong
Journal:  Mult Scler       Date:  2007-02-09       Impact factor: 6.312

8.  Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis.

Authors:  Zoe Fonseca-Kelly; Mayssa Nassrallah; Jorge Uribe; Reas S Khan; Kimberly Dine; Mahasweta Dutt; Kenneth S Shindler
Journal:  Front Neurol       Date:  2012-05-24       Impact factor: 4.003

9.  Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor.

Authors:  Alastair Wilkins; Henry Majed; Robert Layfield; Alastair Compston; Siddharthan Chandran
Journal:  J Neurosci       Date:  2003-06-15       Impact factor: 6.167

10.  Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis.

Authors:  S Anand Trip; Patricio G Schlottmann; Stephen J Jones; Daniel R Altmann; David F Garway-Heath; Alan J Thompson; Gordon T Plant; David H Miller
Journal:  Ann Neurol       Date:  2005-09       Impact factor: 10.422

View more
  8 in total

1.  A Kv1.3 channel-specific blocker alleviates neurological impairment through inhibiting T-cell activation in experimental autoimmune encephalomyelitis.

Authors:  Xiao-Lu Yuan; Yi-Peng Zhao; Jie Huang; Jun-Chen Liu; Wen-Qian Mao; Jun Yin; Bi-Wen Peng; Wan-Hong Liu; Song Han; Xiao-Hua He
Journal:  CNS Neurosci Ther       Date:  2018-03-25       Impact factor: 5.243

2.  Multifocal visual evoked potentials and contrast sensitivity correlate with ganglion cell-inner plexiform layer thickness in multiple sclerosis.

Authors:  Divya Narayanan; Han Cheng; Rosa A Tang; Laura J Frishman
Journal:  Clin Neurophysiol       Date:  2018-11-13       Impact factor: 3.708

3.  Neuroprotective Effect Is Driven Through the Upregulation of CB1 Receptor in Experimental Autoimmune Encephalomyelitis.

Authors:  Zhi-Yin Lou; Wen-Bo Yu; Jie Chen; Lin Li; Li-Sheng Jiang; Bao-Guo Xiao; Zhen-Guo Liu
Journal:  J Mol Neurosci       Date:  2015-09-28       Impact factor: 3.444

4.  A randomized controlled phase II trial of riluzole in early multiple sclerosis.

Authors:  Emmanuelle Waubant; Amir-Hadi Maghzi; Nisha Revirajan; Rebecca Spain; Laura Julian; Ellen M Mowry; Jacqueline Marcus; Shuang Liu; Chengshi Jin; Ari Green; Charles E McCulloch; Daniel Pelletier
Journal:  Ann Clin Transl Neurol       Date:  2014-04-14       Impact factor: 4.511

5.  α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.

Authors:  Michele Rossi; Sabrina Petralla; Michele Protti; Monica Baiula; Tereza Kobrlova; Ondrej Soukup; Santi Mario Spampinato; Laura Mercolini; Barbara Monti; Maria Laura Bolognesi
Journal:  ACS Med Chem Lett       Date:  2020-10-27       Impact factor: 4.345

Review 6.  Hydrogen Ion Dynamics as the Fundamental Link between Neurodegenerative Diseases and Cancer: Its Application to the Therapeutics of Neurodegenerative Diseases with Special Emphasis on Multiple Sclerosis.

Authors:  Salvador Harguindey; Khalid Alfarouk; Julián Polo Orozco; Stephan J Reshkin; Jesús Devesa
Journal:  Int J Mol Sci       Date:  2022-02-23       Impact factor: 5.923

Review 7.  A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis.

Authors:  Laurent Monassier; Ayikoé Guy Mensah-Nyagan; Nicolas Collongues; Guillaume Becker; Valérie Jolivel; Estelle Ayme-Dietrich; Jérôme de Seze; Fabien Binamé; Christine Patte-Mensah
Journal:  Neurol Ther       Date:  2022-05-24

8.  Visual pathway neurodegeneration winged by mitochondrial dysfunction.

Authors:  Axel Petzold; Philip G Nijland; Lisanne J Balk; Angela Maria Amorini; Giacomo Lazzarino; Mike P Wattjes; Claudio Gasperini; Paul van der Valk; Barbara Tavazzi; Giuseppe Lazzarino; Jack van Horssen
Journal:  Ann Clin Transl Neurol       Date:  2014-12-17       Impact factor: 4.511

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.